http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 30 Jun 2026 08:31:26 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Equity+Offerings/NurExone+closes+private+placement+raising+C%24627%2C795/26710238.html <p>NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) has closed a non-brokered private placement of 1,012,573 units at C$0.62 per unit, raising gross proceeds of approximately C$627,795, according to a press release. The closing remains subject to TSX Venture Exchange approval.</p> <p>Each unit consists of one common share and one common share purchase warrant. Each warrant allows the holder to purchase one additional common share at C$0.78 for a period of 36 months from the closing date, subject to an acceleration provision.</p> <p>The acceleration clause allows NurExone to shorten the warrant expiry to 30 days after written notice if the volume weighted average http://www.streetinsider.com/Equity+Offerings/NurExone+closes+private+placement+raising+C%24627%2C795/26710238.html Tue, 30 Jun 2026 08:31:26 -0400 A.36078215 J90 NRX NRXBF O.02555813 O.13737008 http://www.streetinsider.com/Equity+Offerings/NurExone+closes+private+placement+raising+C%24627%2C795/26710238.html <p>NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) has closed a non-brokered private placement of 1,012,573 units at C$0.62 per unit, raising gross proceeds of approximately C$627,795, according to a press release. The closing remains subject to TSX Venture Exchange approval.</p> <p>Each unit consists of one common share and one common share purchase warrant. Each warrant allows the holder to purchase one additional common share at C$0.78 for a period of 36 months from the closing date, subject to an acceleration provision.</p> <p>The acceleration clause allows NurExone to shorten the warrant expiry to 30 days after written notice if the volume weighted average http://www.streetinsider.com/Equity+Offerings/NurExone+closes+private+placement+raising+C%24627%2C795/26710238.html Tue, 30 Jun 2026 08:31:26 -0400 A.36078215 J90 NRX NRXBF O.02555813 O.13737008 http://www.streetinsider.com/Equity+Offerings/NurExone+closes+private+placement+raising+C%24627%2C795/26710238.html <p>NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) has closed a non-brokered private placement of 1,012,573 units at C$0.62 per unit, raising gross proceeds of approximately C$627,795, according to a press release. The closing remains subject to TSX Venture Exchange approval.</p> <p>Each unit consists of one common share and one common share purchase warrant. Each warrant allows the holder to purchase one additional common share at C$0.78 for a period of 36 months from the closing date, subject to an acceleration provision.</p> <p>The acceleration clause allows NurExone to shorten the warrant expiry to 30 days after written notice if the volume weighted average http://www.streetinsider.com/Equity+Offerings/NurExone+closes+private+placement+raising+C%24627%2C795/26710238.html Tue, 30 Jun 2026 08:31:26 -0400 A.36078215 J90 NRX NRXBF O.02555813 O.13737008 http://www.streetinsider.com/Equity+Offerings/NurExone+closes+private+placement+raising+C%24627%2C795/26710238.html <p>NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) has closed a non-brokered private placement of 1,012,573 units at C$0.62 per unit, raising gross proceeds of approximately C$627,795, according to a press release. The closing remains subject to TSX Venture Exchange approval.</p> <p>Each unit consists of one common share and one common share purchase warrant. Each warrant allows the holder to purchase one additional common share at C$0.78 for a period of 36 months from the closing date, subject to an acceleration provision.</p> <p>The acceleration clause allows NurExone to shorten the warrant expiry to 30 days after written notice if the volume weighted average http://www.streetinsider.com/Equity+Offerings/NurExone+closes+private+placement+raising+C%24627%2C795/26710238.html Tue, 30 Jun 2026 08:31:26 -0400 A.36078215 J90 NRX NRXBF O.02555813 O.13737008 http://www.streetinsider.com/Equity+Offerings/NurExone+closes+private+placement+raising+C%24627%2C795/26710238.html <p>NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) has closed a non-brokered private placement of 1,012,573 units at C$0.62 per unit, raising gross proceeds of approximately C$627,795, according to a press release. The closing remains subject to TSX Venture Exchange approval.</p> <p>Each unit consists of one common share and one common share purchase warrant. Each warrant allows the holder to purchase one additional common share at C$0.78 for a period of 36 months from the closing date, subject to an acceleration provision.</p> <p>The acceleration clause allows NurExone to shorten the warrant expiry to 30 days after written notice if the volume weighted average http://www.streetinsider.com/Equity+Offerings/NurExone+closes+private+placement+raising+C%24627%2C795/26710238.html Tue, 30 Jun 2026 08:31:26 -0400 A.36078215 J90 NRX NRXBF O.02555813 O.13737008 http://www.streetinsider.com/Equity+Offerings/NurExone+closes+private+placement+raising+C%24627%2C795/26710238.html <p>NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) has closed a non-brokered private placement of 1,012,573 units at C$0.62 per unit, raising gross proceeds of approximately C$627,795, according to a press release. The closing remains subject to TSX Venture Exchange approval.</p> <p>Each unit consists of one common share and one common share purchase warrant. Each warrant allows the holder to purchase one additional common share at C$0.78 for a period of 36 months from the closing date, subject to an acceleration provision.</p> <p>The acceleration clause allows NurExone to shorten the warrant expiry to 30 days after written notice if the volume weighted average http://www.streetinsider.com/Equity+Offerings/NurExone+closes+private+placement+raising+C%24627%2C795/26710238.html Tue, 30 Jun 2026 08:31:26 -0400 A.36078215 J90 NRX NRXBF O.02555813 O.13737008 http://www.streetinsider.com/Press+Releases/NurExone+Announces+Closing+of+Non-Brokered+Private+Placement/26710233.html <p align="justify">TORONTO, Ontario and HAIFA, Israel, June 30, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“<strong>NurExone</strong>” or the “<strong>Company</strong>”), a biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce that, subject to TSX Venture Exchange (“<strong>TSXV</strong>”) approval, it has closed a non-brokered private placement of 1,012,573 units (“<strong>Units</strong>”) at a price of C$0.62 per Unit for aggregate gross proceeds of approximately C$627,795.26 (the “<strong>Offering</strong>”). The Company intends to use the proceeds of the Offering for general working capital purposes. No insiders participated in this Offering and no finder’s fees were paid http://www.streetinsider.com/Press+Releases/NurExone+Announces+Closing+of+Non-Brokered+Private+Placement/26710233.html Tue, 30 Jun 2026 08:31:00 -0400 A.36078215 J90 NRX NRXBF O.02555813 O.13737008 http://www.streetinsider.com/Press+Releases/NurExone+Announces+Closing+of+Non-Brokered+Private+Placement/26710233.html <p align="justify">TORONTO, Ontario and HAIFA, Israel, June 30, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“<strong>NurExone</strong>” or the “<strong>Company</strong>”), a biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce that, subject to TSX Venture Exchange (“<strong>TSXV</strong>”) approval, it has closed a non-brokered private placement of 1,012,573 units (“<strong>Units</strong>”) at a price of C$0.62 per Unit for aggregate gross proceeds of approximately C$627,795.26 (the “<strong>Offering</strong>”). The Company intends to use the proceeds of the Offering for general working capital purposes. No insiders participated in this Offering and no finder’s fees were paid http://www.streetinsider.com/Press+Releases/NurExone+Announces+Closing+of+Non-Brokered+Private+Placement/26710233.html Tue, 30 Jun 2026 08:31:00 -0400 A.36078215 J90 NRX NRXBF O.02555813 O.13737008 http://www.streetinsider.com/Press+Releases/NurExone+Announces+Closing+of+Non-Brokered+Private+Placement/26710233.html <p align="justify">TORONTO, Ontario and HAIFA, Israel, June 30, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“<strong>NurExone</strong>” or the “<strong>Company</strong>”), a biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce that, subject to TSX Venture Exchange (“<strong>TSXV</strong>”) approval, it has closed a non-brokered private placement of 1,012,573 units (“<strong>Units</strong>”) at a price of C$0.62 per Unit for aggregate gross proceeds of approximately C$627,795.26 (the “<strong>Offering</strong>”). The Company intends to use the proceeds of the Offering for general working capital purposes. No insiders participated in this Offering and no finder’s fees were paid http://www.streetinsider.com/Press+Releases/NurExone+Announces+Closing+of+Non-Brokered+Private+Placement/26710233.html Tue, 30 Jun 2026 08:31:00 -0400 A.36078215 J90 NRX NRXBF O.02555813 O.13737008 http://www.streetinsider.com/Press+Releases/NurExone+Announces+Closing+of+Non-Brokered+Private+Placement/26710233.html <p align="justify">TORONTO, Ontario and HAIFA, Israel, June 30, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“<strong>NurExone</strong>” or the “<strong>Company</strong>”), a biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce that, subject to TSX Venture Exchange (“<strong>TSXV</strong>”) approval, it has closed a non-brokered private placement of 1,012,573 units (“<strong>Units</strong>”) at a price of C$0.62 per Unit for aggregate gross proceeds of approximately C$627,795.26 (the “<strong>Offering</strong>”). The Company intends to use the proceeds of the Offering for general working capital purposes. No insiders participated in this Offering and no finder’s fees were paid http://www.streetinsider.com/Press+Releases/NurExone+Announces+Closing+of+Non-Brokered+Private+Placement/26710233.html Tue, 30 Jun 2026 08:31:00 -0400 A.36078215 J90 NRX NRXBF O.02555813 O.13737008 http://www.streetinsider.com/Press+Releases/NurExone+Announces+Closing+of+Non-Brokered+Private+Placement/26710233.html <p align="justify">TORONTO, Ontario and HAIFA, Israel, June 30, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“<strong>NurExone</strong>” or the “<strong>Company</strong>”), a biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce that, subject to TSX Venture Exchange (“<strong>TSXV</strong>”) approval, it has closed a non-brokered private placement of 1,012,573 units (“<strong>Units</strong>”) at a price of C$0.62 per Unit for aggregate gross proceeds of approximately C$627,795.26 (the “<strong>Offering</strong>”). The Company intends to use the proceeds of the Offering for general working capital purposes. No insiders participated in this Offering and no finder’s fees were paid http://www.streetinsider.com/Press+Releases/NurExone+Announces+Closing+of+Non-Brokered+Private+Placement/26710233.html Tue, 30 Jun 2026 08:31:00 -0400 A.36078215 J90 NRX NRXBF O.02555813 O.13737008 http://www.streetinsider.com/Press+Releases/NurExone+Announces+Closing+of+Non-Brokered+Private+Placement/26710233.html <p align="justify">TORONTO, Ontario and HAIFA, Israel, June 30, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“<strong>NurExone</strong>” or the “<strong>Company</strong>”), a biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce that, subject to TSX Venture Exchange (“<strong>TSXV</strong>”) approval, it has closed a non-brokered private placement of 1,012,573 units (“<strong>Units</strong>”) at a price of C$0.62 per Unit for aggregate gross proceeds of approximately C$627,795.26 (the “<strong>Offering</strong>”). The Company intends to use the proceeds of the Offering for general working capital purposes. No insiders participated in this Offering and no finder’s fees were paid http://www.streetinsider.com/Press+Releases/NurExone+Announces+Closing+of+Non-Brokered+Private+Placement/26710233.html Tue, 30 Jun 2026 08:31:00 -0400 A.36078215 J90 NRX NRXBF O.02555813 O.13737008 http://www.streetinsider.com/Globe+Newswire/NurExone+Announces+Closing+of+Non-Brokered+Private+Placement/26710233.html <p align="justify">TORONTO, Ontario and HAIFA, Israel, June 30, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“<strong>NurExone</strong>” or the “<strong>Company</strong>”), a biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce that, subject to TSX Venture Exchange (“<strong>TSXV</strong>”) approval, it has closed a non-brokered private placement of 1,012,573 units (“<strong>Units</strong>”) at a price of C$0.62 per Unit for aggregate gross proceeds of approximately C$627,795.26 (the “<strong>Offering</strong>”). The Company intends to use the proceeds of the Offering for general working capital purposes. No insiders participated in this Offering and no finder’s fees were paid http://www.streetinsider.com/Globe+Newswire/NurExone+Announces+Closing+of+Non-Brokered+Private+Placement/26710233.html Tue, 30 Jun 2026 08:31:00 -0400 A.36078215 J90 NRX NRXBF O.02555813 O.13737008 http://www.streetinsider.com/Globe+Newswire/NurExone+Announces+Closing+of+Non-Brokered+Private+Placement/26710233.html <p align="justify">TORONTO, Ontario and HAIFA, Israel, June 30, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“<strong>NurExone</strong>” or the “<strong>Company</strong>”), a biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce that, subject to TSX Venture Exchange (“<strong>TSXV</strong>”) approval, it has closed a non-brokered private placement of 1,012,573 units (“<strong>Units</strong>”) at a price of C$0.62 per Unit for aggregate gross proceeds of approximately C$627,795.26 (the “<strong>Offering</strong>”). The Company intends to use the proceeds of the Offering for general working capital purposes. No insiders participated in this Offering and no finder’s fees were paid http://www.streetinsider.com/Globe+Newswire/NurExone+Announces+Closing+of+Non-Brokered+Private+Placement/26710233.html Tue, 30 Jun 2026 08:31:00 -0400 A.36078215 J90 NRX NRXBF O.02555813 O.13737008 http://www.streetinsider.com/Globe+Newswire/NurExone+Announces+Closing+of+Non-Brokered+Private+Placement/26710233.html <p align="justify">TORONTO, Ontario and HAIFA, Israel, June 30, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“<strong>NurExone</strong>” or the “<strong>Company</strong>”), a biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce that, subject to TSX Venture Exchange (“<strong>TSXV</strong>”) approval, it has closed a non-brokered private placement of 1,012,573 units (“<strong>Units</strong>”) at a price of C$0.62 per Unit for aggregate gross proceeds of approximately C$627,795.26 (the “<strong>Offering</strong>”). The Company intends to use the proceeds of the Offering for general working capital purposes. No insiders participated in this Offering and no finder’s fees were paid http://www.streetinsider.com/Globe+Newswire/NurExone+Announces+Closing+of+Non-Brokered+Private+Placement/26710233.html Tue, 30 Jun 2026 08:31:00 -0400 A.36078215 J90 NRX NRXBF O.02555813 O.13737008 http://www.streetinsider.com/Globe+Newswire/NurExone+Announces+Closing+of+Non-Brokered+Private+Placement/26710233.html <p align="justify">TORONTO, Ontario and HAIFA, Israel, June 30, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“<strong>NurExone</strong>” or the “<strong>Company</strong>”), a biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce that, subject to TSX Venture Exchange (“<strong>TSXV</strong>”) approval, it has closed a non-brokered private placement of 1,012,573 units (“<strong>Units</strong>”) at a price of C$0.62 per Unit for aggregate gross proceeds of approximately C$627,795.26 (the “<strong>Offering</strong>”). The Company intends to use the proceeds of the Offering for general working capital purposes. No insiders participated in this Offering and no finder’s fees were paid http://www.streetinsider.com/Globe+Newswire/NurExone+Announces+Closing+of+Non-Brokered+Private+Placement/26710233.html Tue, 30 Jun 2026 08:31:00 -0400 A.36078215 J90 NRX NRXBF O.02555813 O.13737008 http://www.streetinsider.com/Globe+Newswire/NurExone+Announces+Closing+of+Non-Brokered+Private+Placement/26710233.html <p align="justify">TORONTO, Ontario and HAIFA, Israel, June 30, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“<strong>NurExone</strong>” or the “<strong>Company</strong>”), a biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce that, subject to TSX Venture Exchange (“<strong>TSXV</strong>”) approval, it has closed a non-brokered private placement of 1,012,573 units (“<strong>Units</strong>”) at a price of C$0.62 per Unit for aggregate gross proceeds of approximately C$627,795.26 (the “<strong>Offering</strong>”). The Company intends to use the proceeds of the Offering for general working capital purposes. No insiders participated in this Offering and no finder’s fees were paid http://www.streetinsider.com/Globe+Newswire/NurExone+Announces+Closing+of+Non-Brokered+Private+Placement/26710233.html Tue, 30 Jun 2026 08:31:00 -0400 A.36078215 J90 NRX NRXBF O.02555813 O.13737008 http://www.streetinsider.com/Globe+Newswire/NurExone+Announces+Closing+of+Non-Brokered+Private+Placement/26710233.html <p align="justify">TORONTO, Ontario and HAIFA, Israel, June 30, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“<strong>NurExone</strong>” or the “<strong>Company</strong>”), a biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce that, subject to TSX Venture Exchange (“<strong>TSXV</strong>”) approval, it has closed a non-brokered private placement of 1,012,573 units (“<strong>Units</strong>”) at a price of C$0.62 per Unit for aggregate gross proceeds of approximately C$627,795.26 (the “<strong>Offering</strong>”). The Company intends to use the proceeds of the Offering for general working capital purposes. No insiders participated in this Offering and no finder’s fees were paid http://www.streetinsider.com/Globe+Newswire/NurExone+Announces+Closing+of+Non-Brokered+Private+Placement/26710233.html Tue, 30 Jun 2026 08:31:00 -0400 A.36078215 J90 NRX NRXBF O.02555813 O.13737008 http://www.streetinsider.com/Press+Releases/NurExone+Announces+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26579625.html <p align="justify">TORONTO, Ontario and HAIFA, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce its financial results for the first quarter ended March 31, 2026, and to provide a corporate update on recent activities and upcoming milestones.</p> <p align="justify">The Company’s full set of unaudited condensed interim consolidated financial statements for the three months ended March 31, 2026, and accompanying management’s discussion and analysis can be accessed by visiting the Company’s website at <a target="_blank" href="https://www.globenewswire.com/Tracker?data=JU0ulU0FfkHBsxGyOqXXrFrL1aQjOhSP0j6D-MacSBHaBogi2UqlHGH3YT231LzZpkp8MUWK9PSLNM5QTbSjwSAhiFpFXHrixjBiNhEaSSyYL3IPWIEsA-sXzq87NaPcAe5PjqT-BzZ49Pw03c67mjq6LtpsAgtsfhdXAQ4VDG50nz_njRZa4tsE6Zv9dk4G6rvoxLqsDeiEieiLDkBww_3MfuvaVSM4hbyHfJw5c4xmewti45WJbz30P9xw5bYA0J6VahaAcX2R1u0PMTFTIg==" rel="nofollow" http://www.streetinsider.com/Press+Releases/NurExone+Announces+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26579625.html Mon, 01 Jun 2026 08:02:00 -0400 A.28851260 A.36078215 J90 NRX NRXBF O.02555813 O.13737008 O.13812225 http://www.streetinsider.com/Press+Releases/NurExone+Announces+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26579625.html <p align="justify">TORONTO, Ontario and HAIFA, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce its financial results for the first quarter ended March 31, 2026, and to provide a corporate update on recent activities and upcoming milestones.</p> <p align="justify">The Company’s full set of unaudited condensed interim consolidated financial statements for the three months ended March 31, 2026, and accompanying management’s discussion and analysis can be accessed by visiting the Company’s website at <a target="_blank" href="https://www.globenewswire.com/Tracker?data=JU0ulU0FfkHBsxGyOqXXrFrL1aQjOhSP0j6D-MacSBHaBogi2UqlHGH3YT231LzZpkp8MUWK9PSLNM5QTbSjwSAhiFpFXHrixjBiNhEaSSyYL3IPWIEsA-sXzq87NaPcAe5PjqT-BzZ49Pw03c67mjq6LtpsAgtsfhdXAQ4VDG50nz_njRZa4tsE6Zv9dk4G6rvoxLqsDeiEieiLDkBww_3MfuvaVSM4hbyHfJw5c4xmewti45WJbz30P9xw5bYA0J6VahaAcX2R1u0PMTFTIg==" rel="nofollow" http://www.streetinsider.com/Press+Releases/NurExone+Announces+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26579625.html Mon, 01 Jun 2026 08:02:00 -0400 A.28851260 A.36078215 J90 NRX NRXBF O.02555813 O.13737008 O.13812225 http://www.streetinsider.com/Press+Releases/NurExone+Announces+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26579625.html <p align="justify">TORONTO, Ontario and HAIFA, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce its financial results for the first quarter ended March 31, 2026, and to provide a corporate update on recent activities and upcoming milestones.</p> <p align="justify">The Company’s full set of unaudited condensed interim consolidated financial statements for the three months ended March 31, 2026, and accompanying management’s discussion and analysis can be accessed by visiting the Company’s website at <a target="_blank" href="https://www.globenewswire.com/Tracker?data=JU0ulU0FfkHBsxGyOqXXrFrL1aQjOhSP0j6D-MacSBHaBogi2UqlHGH3YT231LzZpkp8MUWK9PSLNM5QTbSjwSAhiFpFXHrixjBiNhEaSSyYL3IPWIEsA-sXzq87NaPcAe5PjqT-BzZ49Pw03c67mjq6LtpsAgtsfhdXAQ4VDG50nz_njRZa4tsE6Zv9dk4G6rvoxLqsDeiEieiLDkBww_3MfuvaVSM4hbyHfJw5c4xmewti45WJbz30P9xw5bYA0J6VahaAcX2R1u0PMTFTIg==" rel="nofollow" http://www.streetinsider.com/Press+Releases/NurExone+Announces+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26579625.html Mon, 01 Jun 2026 08:02:00 -0400 A.28851260 A.36078215 J90 NRX NRXBF O.02555813 O.13737008 O.13812225 http://www.streetinsider.com/Press+Releases/NurExone+Announces+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26579625.html <p align="justify">TORONTO, Ontario and HAIFA, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce its financial results for the first quarter ended March 31, 2026, and to provide a corporate update on recent activities and upcoming milestones.</p> <p align="justify">The Company’s full set of unaudited condensed interim consolidated financial statements for the three months ended March 31, 2026, and accompanying management’s discussion and analysis can be accessed by visiting the Company’s website at <a target="_blank" href="https://www.globenewswire.com/Tracker?data=JU0ulU0FfkHBsxGyOqXXrFrL1aQjOhSP0j6D-MacSBHaBogi2UqlHGH3YT231LzZpkp8MUWK9PSLNM5QTbSjwSAhiFpFXHrixjBiNhEaSSyYL3IPWIEsA-sXzq87NaPcAe5PjqT-BzZ49Pw03c67mjq6LtpsAgtsfhdXAQ4VDG50nz_njRZa4tsE6Zv9dk4G6rvoxLqsDeiEieiLDkBww_3MfuvaVSM4hbyHfJw5c4xmewti45WJbz30P9xw5bYA0J6VahaAcX2R1u0PMTFTIg==" rel="nofollow" http://www.streetinsider.com/Press+Releases/NurExone+Announces+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26579625.html Mon, 01 Jun 2026 08:02:00 -0400 A.28851260 A.36078215 J90 NRX NRXBF O.02555813 O.13737008 O.13812225 http://www.streetinsider.com/Press+Releases/NurExone+Announces+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26579625.html <p align="justify">TORONTO, Ontario and HAIFA, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce its financial results for the first quarter ended March 31, 2026, and to provide a corporate update on recent activities and upcoming milestones.</p> <p align="justify">The Company’s full set of unaudited condensed interim consolidated financial statements for the three months ended March 31, 2026, and accompanying management’s discussion and analysis can be accessed by visiting the Company’s website at <a target="_blank" href="https://www.globenewswire.com/Tracker?data=JU0ulU0FfkHBsxGyOqXXrFrL1aQjOhSP0j6D-MacSBHaBogi2UqlHGH3YT231LzZpkp8MUWK9PSLNM5QTbSjwSAhiFpFXHrixjBiNhEaSSyYL3IPWIEsA-sXzq87NaPcAe5PjqT-BzZ49Pw03c67mjq6LtpsAgtsfhdXAQ4VDG50nz_njRZa4tsE6Zv9dk4G6rvoxLqsDeiEieiLDkBww_3MfuvaVSM4hbyHfJw5c4xmewti45WJbz30P9xw5bYA0J6VahaAcX2R1u0PMTFTIg==" rel="nofollow" http://www.streetinsider.com/Press+Releases/NurExone+Announces+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26579625.html Mon, 01 Jun 2026 08:02:00 -0400 A.28851260 A.36078215 J90 NRX NRXBF O.02555813 O.13737008 O.13812225 http://www.streetinsider.com/Press+Releases/NurExone+Announces+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26579625.html <p align="justify">TORONTO, Ontario and HAIFA, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce its financial results for the first quarter ended March 31, 2026, and to provide a corporate update on recent activities and upcoming milestones.</p> <p align="justify">The Company’s full set of unaudited condensed interim consolidated financial statements for the three months ended March 31, 2026, and accompanying management’s discussion and analysis can be accessed by visiting the Company’s website at <a target="_blank" href="https://www.globenewswire.com/Tracker?data=JU0ulU0FfkHBsxGyOqXXrFrL1aQjOhSP0j6D-MacSBHaBogi2UqlHGH3YT231LzZpkp8MUWK9PSLNM5QTbSjwSAhiFpFXHrixjBiNhEaSSyYL3IPWIEsA-sXzq87NaPcAe5PjqT-BzZ49Pw03c67mjq6LtpsAgtsfhdXAQ4VDG50nz_njRZa4tsE6Zv9dk4G6rvoxLqsDeiEieiLDkBww_3MfuvaVSM4hbyHfJw5c4xmewti45WJbz30P9xw5bYA0J6VahaAcX2R1u0PMTFTIg==" rel="nofollow" http://www.streetinsider.com/Press+Releases/NurExone+Announces+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26579625.html Mon, 01 Jun 2026 08:02:00 -0400 A.28851260 A.36078215 J90 NRX NRXBF O.02555813 O.13737008 O.13812225 http://www.streetinsider.com/Press+Releases/NurExone+Announces+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26579625.html <p align="justify">TORONTO, Ontario and HAIFA, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce its financial results for the first quarter ended March 31, 2026, and to provide a corporate update on recent activities and upcoming milestones.</p> <p align="justify">The Company’s full set of unaudited condensed interim consolidated financial statements for the three months ended March 31, 2026, and accompanying management’s discussion and analysis can be accessed by visiting the Company’s website at <a target="_blank" href="https://www.globenewswire.com/Tracker?data=JU0ulU0FfkHBsxGyOqXXrFrL1aQjOhSP0j6D-MacSBHaBogi2UqlHGH3YT231LzZpkp8MUWK9PSLNM5QTbSjwSAhiFpFXHrixjBiNhEaSSyYL3IPWIEsA-sXzq87NaPcAe5PjqT-BzZ49Pw03c67mjq6LtpsAgtsfhdXAQ4VDG50nz_njRZa4tsE6Zv9dk4G6rvoxLqsDeiEieiLDkBww_3MfuvaVSM4hbyHfJw5c4xmewti45WJbz30P9xw5bYA0J6VahaAcX2R1u0PMTFTIg==" rel="nofollow" http://www.streetinsider.com/Press+Releases/NurExone+Announces+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26579625.html Mon, 01 Jun 2026 08:02:00 -0400 A.28851260 A.36078215 J90 NRX NRXBF O.02555813 O.13737008 O.13812225